Loading…

Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer

Cancer at the lower end of the digestive tract, colorectal cancer (CRC), starts with asymptomatic polyps, which can be diagnosed as cancer at a later stage. It is the fourth leading cause of malignancy-associated mortality worldwide. Despite progress in conventional treatment strategies, the possibi...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials advances 2023-10, Vol.153, p.213556-213556, Article 213556
Main Authors: Choudhury, Hira, Pandey, Manisha, Saravanan, Vilashini, Mun, Amanda Tan Yee, Bhattamisra, Subrat Kumar, Parikh, Ankit, Garg, Sanjay, Gorain, Bapi
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083
cites cdi_FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083
container_end_page 213556
container_issue
container_start_page 213556
container_title Biomaterials advances
container_volume 153
creator Choudhury, Hira
Pandey, Manisha
Saravanan, Vilashini
Mun, Amanda Tan Yee
Bhattamisra, Subrat Kumar
Parikh, Ankit
Garg, Sanjay
Gorain, Bapi
description Cancer at the lower end of the digestive tract, colorectal cancer (CRC), starts with asymptomatic polyps, which can be diagnosed as cancer at a later stage. It is the fourth leading cause of malignancy-associated mortality worldwide. Despite progress in conventional treatment strategies, the possibility to overcome the mortality and morbidity issues with the enhancement of the lifespan of CRC patients is limited. With the advent of nanocarrier-based drug delivery systems, a promising revolution has been made in diagnosis, treatment, and theranostic purposes for cancer management. Herein, we reviewed the progress of miniaturized nanocarriers, such as liposomes, niosomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles, employed in passive and active targeting and their role in theranostic applications in CRC. With this novel scope, the diagnosis and treatment of CRC have proceeded to the forefront of innovation, where specific characteristics of the nanocarriers, such as processability, flexibility in developing precise architecture, improved circulation, site-specific delivery, and rapid response, facilitate the management of cancer patients. Furthermore, surface-engineered technologies for the nanocarriers could involve receptor-mediated deliveries towards the overexpressed receptors on the CRC microenvironment. Moreover, the potential of clinical translation of these targeted miniaturized formulations as well as the possible limitations and barriers that could impact this translation into clinical practice were highlighted. The advancement of these newest developments in clinical research and progress into the commercialization stage gives hope for a better tomorrow.
doi_str_mv 10.1016/j.bioadv.2023.213556
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2841027609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2841027609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083</originalsourceid><addsrcrecordid>eNpNkMtKLDEQhoMoKuobiGTpwhkrl073LEWOFxAE0XWork6PGXqSNskI5-0dbRVXdf3r8jF2KmAuQJjL1bz1Ebv3uQSp5lKoqjI77FDWtZwtKmh2__gH7CTnFQAoqUxVqX12oGpdN3UNh-z9yZELhY8pLpPLmceeF0xLV1zHA4ZImJJ3KXMfeOdxGWIuni54eXUJR7f5CjB0U2KqchzHwRMWH8OXkOIQk6OCAycM5NIx2-txyO7k2x6xl5t_z9d3s4fH2_vrq4cZKSPLTKvGtEJSW2mB29uhbzWBNqRQSWm6Tqi2aw22C9MTgRCke0GVBgRjEBp1xM6nudv_3jYuF7v2mdwwYHBxk61stABZG1hsW_XUSinmnFxvx-TXmP5bAfYTul3ZCbr9hG4n6FvZ2feGTbt23a_oB7H6AFIQgWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2841027609</pqid></control><display><type>article</type><title>Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer</title><source>ScienceDirect Journals</source><creator>Choudhury, Hira ; Pandey, Manisha ; Saravanan, Vilashini ; Mun, Amanda Tan Yee ; Bhattamisra, Subrat Kumar ; Parikh, Ankit ; Garg, Sanjay ; Gorain, Bapi</creator><creatorcontrib>Choudhury, Hira ; Pandey, Manisha ; Saravanan, Vilashini ; Mun, Amanda Tan Yee ; Bhattamisra, Subrat Kumar ; Parikh, Ankit ; Garg, Sanjay ; Gorain, Bapi</creatorcontrib><description>Cancer at the lower end of the digestive tract, colorectal cancer (CRC), starts with asymptomatic polyps, which can be diagnosed as cancer at a later stage. It is the fourth leading cause of malignancy-associated mortality worldwide. Despite progress in conventional treatment strategies, the possibility to overcome the mortality and morbidity issues with the enhancement of the lifespan of CRC patients is limited. With the advent of nanocarrier-based drug delivery systems, a promising revolution has been made in diagnosis, treatment, and theranostic purposes for cancer management. Herein, we reviewed the progress of miniaturized nanocarriers, such as liposomes, niosomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles, employed in passive and active targeting and their role in theranostic applications in CRC. With this novel scope, the diagnosis and treatment of CRC have proceeded to the forefront of innovation, where specific characteristics of the nanocarriers, such as processability, flexibility in developing precise architecture, improved circulation, site-specific delivery, and rapid response, facilitate the management of cancer patients. Furthermore, surface-engineered technologies for the nanocarriers could involve receptor-mediated deliveries towards the overexpressed receptors on the CRC microenvironment. Moreover, the potential of clinical translation of these targeted miniaturized formulations as well as the possible limitations and barriers that could impact this translation into clinical practice were highlighted. The advancement of these newest developments in clinical research and progress into the commercialization stage gives hope for a better tomorrow.</description><identifier>ISSN: 2772-9508</identifier><identifier>EISSN: 2772-9508</identifier><identifier>DOI: 10.1016/j.bioadv.2023.213556</identifier><identifier>PMID: 37478770</identifier><language>eng</language><publisher>Netherlands</publisher><ispartof>Biomaterials advances, 2023-10, Vol.153, p.213556-213556, Article 213556</ispartof><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083</citedby><cites>FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37478770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choudhury, Hira</creatorcontrib><creatorcontrib>Pandey, Manisha</creatorcontrib><creatorcontrib>Saravanan, Vilashini</creatorcontrib><creatorcontrib>Mun, Amanda Tan Yee</creatorcontrib><creatorcontrib>Bhattamisra, Subrat Kumar</creatorcontrib><creatorcontrib>Parikh, Ankit</creatorcontrib><creatorcontrib>Garg, Sanjay</creatorcontrib><creatorcontrib>Gorain, Bapi</creatorcontrib><title>Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer</title><title>Biomaterials advances</title><addtitle>Biomater Adv</addtitle><description>Cancer at the lower end of the digestive tract, colorectal cancer (CRC), starts with asymptomatic polyps, which can be diagnosed as cancer at a later stage. It is the fourth leading cause of malignancy-associated mortality worldwide. Despite progress in conventional treatment strategies, the possibility to overcome the mortality and morbidity issues with the enhancement of the lifespan of CRC patients is limited. With the advent of nanocarrier-based drug delivery systems, a promising revolution has been made in diagnosis, treatment, and theranostic purposes for cancer management. Herein, we reviewed the progress of miniaturized nanocarriers, such as liposomes, niosomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles, employed in passive and active targeting and their role in theranostic applications in CRC. With this novel scope, the diagnosis and treatment of CRC have proceeded to the forefront of innovation, where specific characteristics of the nanocarriers, such as processability, flexibility in developing precise architecture, improved circulation, site-specific delivery, and rapid response, facilitate the management of cancer patients. Furthermore, surface-engineered technologies for the nanocarriers could involve receptor-mediated deliveries towards the overexpressed receptors on the CRC microenvironment. Moreover, the potential of clinical translation of these targeted miniaturized formulations as well as the possible limitations and barriers that could impact this translation into clinical practice were highlighted. The advancement of these newest developments in clinical research and progress into the commercialization stage gives hope for a better tomorrow.</description><issn>2772-9508</issn><issn>2772-9508</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpNkMtKLDEQhoMoKuobiGTpwhkrl073LEWOFxAE0XWork6PGXqSNskI5-0dbRVXdf3r8jF2KmAuQJjL1bz1Ebv3uQSp5lKoqjI77FDWtZwtKmh2__gH7CTnFQAoqUxVqX12oGpdN3UNh-z9yZELhY8pLpPLmceeF0xLV1zHA4ZImJJ3KXMfeOdxGWIuni54eXUJR7f5CjB0U2KqchzHwRMWH8OXkOIQk6OCAycM5NIx2-txyO7k2x6xl5t_z9d3s4fH2_vrq4cZKSPLTKvGtEJSW2mB29uhbzWBNqRQSWm6Tqi2aw22C9MTgRCke0GVBgRjEBp1xM6nudv_3jYuF7v2mdwwYHBxk61stABZG1hsW_XUSinmnFxvx-TXmP5bAfYTul3ZCbr9hG4n6FvZ2feGTbt23a_oB7H6AFIQgWQ</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Choudhury, Hira</creator><creator>Pandey, Manisha</creator><creator>Saravanan, Vilashini</creator><creator>Mun, Amanda Tan Yee</creator><creator>Bhattamisra, Subrat Kumar</creator><creator>Parikh, Ankit</creator><creator>Garg, Sanjay</creator><creator>Gorain, Bapi</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer</title><author>Choudhury, Hira ; Pandey, Manisha ; Saravanan, Vilashini ; Mun, Amanda Tan Yee ; Bhattamisra, Subrat Kumar ; Parikh, Ankit ; Garg, Sanjay ; Gorain, Bapi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choudhury, Hira</creatorcontrib><creatorcontrib>Pandey, Manisha</creatorcontrib><creatorcontrib>Saravanan, Vilashini</creatorcontrib><creatorcontrib>Mun, Amanda Tan Yee</creatorcontrib><creatorcontrib>Bhattamisra, Subrat Kumar</creatorcontrib><creatorcontrib>Parikh, Ankit</creatorcontrib><creatorcontrib>Garg, Sanjay</creatorcontrib><creatorcontrib>Gorain, Bapi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomaterials advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choudhury, Hira</au><au>Pandey, Manisha</au><au>Saravanan, Vilashini</au><au>Mun, Amanda Tan Yee</au><au>Bhattamisra, Subrat Kumar</au><au>Parikh, Ankit</au><au>Garg, Sanjay</au><au>Gorain, Bapi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer</atitle><jtitle>Biomaterials advances</jtitle><addtitle>Biomater Adv</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>153</volume><spage>213556</spage><epage>213556</epage><pages>213556-213556</pages><artnum>213556</artnum><issn>2772-9508</issn><eissn>2772-9508</eissn><abstract>Cancer at the lower end of the digestive tract, colorectal cancer (CRC), starts with asymptomatic polyps, which can be diagnosed as cancer at a later stage. It is the fourth leading cause of malignancy-associated mortality worldwide. Despite progress in conventional treatment strategies, the possibility to overcome the mortality and morbidity issues with the enhancement of the lifespan of CRC patients is limited. With the advent of nanocarrier-based drug delivery systems, a promising revolution has been made in diagnosis, treatment, and theranostic purposes for cancer management. Herein, we reviewed the progress of miniaturized nanocarriers, such as liposomes, niosomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles, employed in passive and active targeting and their role in theranostic applications in CRC. With this novel scope, the diagnosis and treatment of CRC have proceeded to the forefront of innovation, where specific characteristics of the nanocarriers, such as processability, flexibility in developing precise architecture, improved circulation, site-specific delivery, and rapid response, facilitate the management of cancer patients. Furthermore, surface-engineered technologies for the nanocarriers could involve receptor-mediated deliveries towards the overexpressed receptors on the CRC microenvironment. Moreover, the potential of clinical translation of these targeted miniaturized formulations as well as the possible limitations and barriers that could impact this translation into clinical practice were highlighted. The advancement of these newest developments in clinical research and progress into the commercialization stage gives hope for a better tomorrow.</abstract><cop>Netherlands</cop><pmid>37478770</pmid><doi>10.1016/j.bioadv.2023.213556</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2772-9508
ispartof Biomaterials advances, 2023-10, Vol.153, p.213556-213556, Article 213556
issn 2772-9508
2772-9508
language eng
recordid cdi_proquest_miscellaneous_2841027609
source ScienceDirect Journals
title Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A23%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20progress%20of%20targeted%20nanocarriers%20in%20diagnostic,%20therapeutic,%20and%20theranostic%20applications%20in%20colorectal%20cancer&rft.jtitle=Biomaterials%20advances&rft.au=Choudhury,%20Hira&rft.date=2023-10-01&rft.volume=153&rft.spage=213556&rft.epage=213556&rft.pages=213556-213556&rft.artnum=213556&rft.issn=2772-9508&rft.eissn=2772-9508&rft_id=info:doi/10.1016/j.bioadv.2023.213556&rft_dat=%3Cproquest_cross%3E2841027609%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-4386b12cb541a6550fb4c046c3a3226dd13bdb6ab96fcc011c4f1c540a066a083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2841027609&rft_id=info:pmid/37478770&rfr_iscdi=true